Download PDF
Thromb Haemost 1984; 51(01): 097-098
DOI: 10.1055/s-0038-1661029
Original Article
Schattauer GmbH Stuttgart

Effect of 24 Hours of Normoglycaemia on Tissue-Type Plasminogen Activator Plasma Levels in Insulin Dependent Diabetes

I Juhan-Vague
1   The Lab. of Haematology, Hospital Timone, University of Marseille, France
,
P Vague
2   The Dept, of Diabetology, Hospital Michel Lévy, University of Marseille, France
,
C Poisson
1   The Lab. of Haematology, Hospital Timone, University of Marseille, France
,
M F Aillaud
1   The Lab. of Haematology, Hospital Timone, University of Marseille, France
,
C Mendez
1   The Lab. of Haematology, Hospital Timone, University of Marseille, France
,
D Collen
3   The Center of Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 18 July 1983

Accepted 24 November 1983

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have previously demonstrated that a short period of normoglycaemia obtained through an artificial pancreas in uncontrolled insulin-dependent diabetics improves parameters of the functional microangiopathy such as erythrocyte deformability and platelet aggregation. Because recently an immunoradiometric assay for tissue plasminogen activator (t-PA) was developed we measured t-PA levels in 18 uncontrolled insulin-dependent diabetics before and after 24 hr of normoglycaemia induced by insulin to look for a modification of endothelial cells function. After 24 hr of strict control, plasma free insulin levels rose significantly, total t-PA R-Ag, its active fibrin binding fraction and euglobulin fibrinolytic activity were significantly decreased. These results suggest a responsibility for insulin in the decrease in t-PA blood level and could explain at least partially the relation between hyperinsulinism, thrombosis and atherogenesis.

Key Words

Tissue type plasminogen activator - Insulin dependent diabetes - Artificial pancreas
 

  • References

  • 1 Aimer LO, Nilsson IM. Fibrinolytic activity and treatment of diabetes. Lancet 1974; 1: 1342
    PubMedGoogle Scholar
  • 2 Sharma SS. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile onset and maturity onset diabetes mellitus. J Clin Pathol 1981; 34: 501-503
    CrossrefPubMedGoogle Scholar
  • 3 Almer LO, Sundkvist G, Lilja B. Endothelial factors, toe temperature and leg circulation in diabetics with and without autonomic neuropathy. Thromb Res 1982; 26: 119-128
    CrossrefPubMedGoogle Scholar
  • 4 Farid NR, Anderson J, Martin A, Weightman D. Fibrinolytic activity and treatment of diabetes. Lancet 1974; 1: 631-632
    PubMedGoogle Scholar
  • 5 Lassman HB, Wilkens HJ, Back N. Biochemical pharmacology of the fibrinolysin system of the rat. I. The effect of alloxan-induced hyperglycemia. J. Pharmacol Exp Ther 1974; 189: 317-326
    PubMedGoogle Scholar
  • 6 Smokovitis A, Auerswald W, Binder BR. The effect of alloxan induced diabetes on tissue plasminogen activator activity and plasmin inhibition in the rat. Thromb Res 1981; 23: 421-134
    CrossrefPubMedGoogle Scholar
  • 7 Juhan I, Vague P, Buonocore M, Moulin JP, Jouve R, Vialettes B. Abnormalities of erythrocyte deformability and platelet aggregation in insulin dependent diabetics corrected by insulin in vivo and in vitro. Lancet 1982; 1: 535-537
    PubMedGoogle Scholar
  • 8 Rijken DC, Juhan-Vague I, De Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site radioimmunometric assay. J Lab Clin Med 1983; 101: 274-284
    PubMedGoogle Scholar
  • 9 Rijken DC, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med 1983; 101: 285-294
    PubMedGoogle Scholar
  • 10 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fraction on the fibrin plate. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (eds) Raven Press; New York: 1976. 2 57-65
    Google Scholar
  • 11 Hales CN, Randle PJ. Immuno assay of insulin with insulin antibody precipitate. Biochem J 1963; 88: 137-146
    CrossrefPubMedGoogle Scholar
  • 12 Juhan-Vague I, Rijken DC, De Cock F, Mendez C, Collen D. Extrinsic plasminogen activator levels in clinical plasma samples. In: Progress in fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. Eds Churchill Livingstone, Edinburgh; London, Melbourne, New York: 1983. 6 65-69
    Google Scholar
  • 13 Fearnley GR, Vincent CT, Chakrabarti R. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet 1959; 2: 1067
    PubMedGoogle Scholar
  • 14 Hedlin AM. Insulin and blood fibrinolytic activity. Thrombos Diathes Haemorrh 1973; 29: 293-299
    PubMedGoogle Scholar
  • 15 Verstraete M, Amery A, Maes H, Vermylen J. Influence of chlorpropamide and glucose on fibrinolytic activity. J Lab CUn Med 1963; 61: 926-934
    PubMedGoogle Scholar
  • 16 Lassman HB, Back N. Biochemical pharmacology of the fibrinolytic system of the rat. II. The effect of insulin-induced hypoglycemia. J Pharmacol Exp Therap 1974; 189: 327-332
    PubMedGoogle Scholar
  • 17 Wilkens HJ, Back N. Fibrinolysis and risk factors of atherosclerotic disease, with special emphasis on diabetes mellitus. Circ Shock 1978; 5: 125-143
    PubMedGoogle Scholar
  • 18 Kaiser N, Vlodavsky I, Tursinai A, Fukz Z, Cerasi E. Binding, internalization and degradation of insulin in vascular endothelial cells. Diabetes 1982; 31: 1077-1083
    CrossrefPubMedGoogle Scholar
  • 19 Stout RW, Vallance OwenJ. Insulin and atheroma. Lancet 1969; 1: 1078-1080
    PubMedGoogle Scholar